Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646199 | 1.00 | GCK (0.81) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646397 | 1.00 | GCK (0.81) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646026 | 1.00 | GCK (0.81) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646391 | 1.00 | GCK (0.81) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646202 | 1.00 | GCK (0.81) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646021 | 0.99 | GCK (0.83) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2646024 | 0.99 | GCK (0.83) | GCKTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2653900 | 0.91 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL2653899 | 0.91 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL3388757 | 0.90 | GCK (1.00) | GCKMEN1KMT2AALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | claimed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | claimed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | claimed |
| WO-2006043036-A2 | TREATMENT OF DIABETES | THE UNIVERSITY OF NEWCASTLE (GB) | 2006-04-27 | — | — | WO | disclosed |
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |